A randomized, double-blind, placebo managed, period III medical trial evaluated the efficacy and protection profile of adalimumab to be a monotherapy in people with RA who had unsuccessful to answer csDMARDs [191]. The effects showed equally statistically substantial improvement from the ailment activity and an excellent basic safety profile. On th